Table 4.
Drug Name | Formulation | In Vitro Models | Mouse Models | Human Trials |
---|---|---|---|---|
INCB7839/ Aderbasib |
Small molecule inhibitor | HER2 + breast cancer with trastuzumab [156] | High-grade glioma xenograft tumour model [157] | Phase I; paediatric glioma [150] |
Phase I/II; DLBCL in combination with rituximab, post autologous HCT [149] | ||||
HER2+ breast cancer xenograft tumour model with trastuzumab [156] | Phase I; HER2+ metastatic breast cancer with trastuzumab [158] |
|||
BMS-561392/ DPC-333 | Small molecule inhibitor | NSCLC [159] | Collagen-induced arthritis (CIA) model [161] | Phase II rheumatoid arthritis [161] |
Autoimmune hepatitis [162] | ||||
Alzheimer’s [160] | Acute colitis [163] | |||
Alzheimer’s model [160] | ||||
Spinal cord injury [164] | ||||
TMI-005/ Apratastat |
Small molecule inhibitor | Polycystic kidney disease [165]. | SARS-CoV-2 [166] | Phase II clinical trial for rheumatoid arthritis [152]. |
NSCLC [167]. | ||||
JTP-96193 | Small molecule inhibitor | Type 2 diabetes & diabetic peripheral neuropathy [168]. |
||
D1(A12) | Human IgG antibody |
HNSCC [169]. | Ovarian xenograft tumour model [170]. | |
Triple negative breast cancer [171] | ||||
A9(B8) | Humanised mouse IgG2 antibody |
NSCLC with erlotinib/ gefitinib [172]. |
Pancreatic cancer [173]. | |
MEDI3622 | Humanised mouse IgG1 antibody |
Colorectal cancer [174]. | Head and neck & colorectal xenograft tumour models [175] | |
Ovarian cancer & Burkitt’s lymphoma [176] | Polymicrobial sepsis [177]. |